Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)

被引：1

作者：

Francolini, Giulio ^{[1
]}

Bertini, Niccolo ^{[2
]}

Di Cataldo, Vanessa ^{[1
]}

Garlatti, Pietro ^{[1
]}

Aquilano, Michele ^{[3
]}

Caini, Saverio ^{[4
]}

Bruni, Alessio ^{[5
]}

Ingrosso, Gianluca ^{[6
]}

D'angelillo, Rolando Maria ^{[7
]}

Tagliaferri, Luca ^{[8
]}

Augugliaro, Matteo ^{[9
]}

Triggiani, Luca ^{[10
]}

Parisi, Silvana ^{[11
]}

Timon, Giorgia ^{[9
]}

Arcidiacono, Fabio ^{[12
]}

Marvaso, Giulia ^{[13
]}

Jereczek-Fossa, Barbara Alicja ^{[13
]}

Lancia, Andrea ^{[14
]}

Franzese, Ciro ^{[15
]}

Alongi, Filippo ^{[16
]}

Simontacchi, Gabriele ^{[1
]}

Greto, Daniela ^{[1
]}

Bonomo, Pierluigi ^{[1
]}

Loi, Mauro ^{[1
]}

Frosini, Giulio ^{[2
]}

Burchini, Luca ^{[2
]}

Desideri, Isacco ^{[2
]}

Meattini, Icro ^{[2
]}

Valicenti, Richard K. ^{[17
]}

Livi, Lorenzo ^{[2
]}

机构：

[1] Univ Careggi Florence, Azienda Osped Univ Careggi, Radiat Oncol Unit, Florence, Italy

[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy

[3] IFCA, Ist Fiorentino Cura Assistenza, Cyberknife Unit, Florence, Italy

[4] Inst Canc Res Prevent & Clin Network ISPRO, Canc Risk Factors & Lifestyle Epidemiol Unit, Florence, Italy

[5] Univ Hosp Modena, Dept Oncol & Hematol, Radiat Oncol Unit, Modena, Italy

[6] Univ Perugia, Dept Med & Surg, Radiat Oncol Sect, Perugia, Italy

[7] Univ Roma Tor Vergata, Dept Biomed & Prevent, Radiat Oncol, Rome, Italy

[8] Fdn Policlin Univ A Gemelli, IRCCS, Dipartimento Diagnost Immagini Radioterapia Oncolo, UOC Radioterapia Oncolog, Rome, Italy

[9] Azienda USL IRCCS Reggio Emilia, Unit Radiotherapy, Reggio Emilia, Italy

[10] Univ Studi Brescia, Dept Radiat Oncol, Brescia, Italy

[11] Univ Messina, Dept Biomed Dent Sci & Morphol & Funct Imaging, Radiat Oncol Unit, Messina, Italy

[12] S Maria Hosp, Radiat Oncol Ctr, Terni, Italy

[13] IRCCS, European Inst Oncol, IEO, Div Radiat Oncol, Milan, Italy

[14] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy

[15] IRCCS, Human Clin & Res Ctr, Dept Radiotherapy & Radiosurg, Milan, Italy

[16] IRCCS Sacro Cuore Don Calabria Hosp, Dept Adv Radiat Oncol, Negrar, Verona, Italy

[17] Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA USA

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2025年

关键词：

THERAPY;

D O I：

10.1038/s41391-025-00950-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate resistant prostate cancer (omCRPC). The object of the current analysis is to explore whether the benefit provided by SBRT to AAP is maintained at later stages of disease after oligoprogressionMethodsPatients enrolled in ARTO trial in whom a first progression event was reported were divided in two groups according to the treatment approach received, regardless of the initial randomization. After first progression event, Patients in Group A received SBRT on oligoprogressive disease, while patients in group B received second line systemic treatment. Palliative RT was not considered for the purpose of this analysis. Progression-Free survival (PFS) 1 and 2 were defined as time between AAP start and first progression event and time between first and second progression event, death or last follow up, (whichever came first), respectively. Cox regression analysis was performed to compare PFS1 + PFS2 in patients in group A vs Group B. Kaplan-Meier analysis was performed to compare overall survival between the two groupsResultsMedian PFS1 + PFS2 was 45.9 months vs. not reached in group A (n = 43) vs Group B (n = 20), respectively (HR 0.63, 95% CI 0.17-2.33, p value 0.489), no significant difference was detected. Median OS was not reached in neither of the two arms of treatment, with a non-significant trend in favour of the experimental arm (HR 0.50, 95% CI 0.14-1.78, p = 0.284)ConclusionsResults from the present analysis show that SBRT after progression may be a viable and feasible option for omCRPC after progression if compared to second line systemic therapy

引用

页数：5

共 23 条

[1] Francolini G., Allegra A.G., Detti B., Di Cataldo V., Caini S., Bruni A., Et al., Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO), J Clin Oncol, 41, pp. 5561-5568, (2023)
[2] de Bono J., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Et al., Olaparib for metastatic castration-resistant prostate cancer, N. Engl J Med, 382, pp. 2091-2102, (2020)
[3] Sartor O., de Bono J., Chi K.N., Fizazi K., Herrmann K., Rahbar K., Et al., Lutetium-177-PSMA-617 for metastatic castration- resistant prostate cancer, N. Engl J Med, 385, pp. 1091-1103, (2021)
[4] Chi K.N., Chowdhury S., Bjartell A., Chung B.H., Pereira de Santana Gomes A.J., Et al., Apalutamide in patients with metastatic castration- sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN Study, J Clin Oncol, 39, pp. 2294-2303, (2021)
[5] Armstrong A.J., Azad A.A., Iguchi T., Szmulewitz R.Z., Petrylak D.P., Holzbeierlein J., Et al., Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 40, pp. 1616-1622, (2022)
[6] Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y., Et al., Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, pp. 686-700, (2019)
[7] Fizazi K., Foulon S., Carles J., Roubaud G., McDermott R., Flechon A., Et al., Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design, Lancet, 399, pp. 1695-1707, (2022)
[8] Smith M.R., Hussain M., Saad F., Fizazi K., Sternberg C.N., Crawford E.D., Et al., Darolutamide and survival in metastatic, hormone- sensitive prostate cancer, N. Engl J Med, 386, pp. 1132-1142, (2022)
[9] Gillessen S., Bossi A., Davis I.D., de Bono J., Fizazi K., James N.D., Et al., Management of patients with advanced prostate cancer- metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022, Eur J Cancer, 185, pp. 178-215, (2023)
[10] Triggiani L., Alongi F., Buglione M., Detti B., Santoni R., Bruni A., Et al., Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study, Br J Cancer, 116, pp. 1520-1525, (2017)

← 1 2 3 →